David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 317



191
TITLE: Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia  Full Text
AUTHORS: Davidson, B; Nagel, C; King, M; Skorpinski, T; Kehoe, S; Richardson, D; David Scott Miller ; Lea, J;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
192
TITLE: Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?  Full Text
AUTHORS: Nagel, C; Garcia-Soto, A; Richardson, D; Lea, J; David Scott Miller ; Kehoe, S;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
193
TITLE: Outcomes of third line chemotherapy for recurrent and persistent cervical cancer  Full Text
AUTHORS: D.B Manders; S.C Purinton; J.S Lea; David Scott Miller ; S.M Kehoe; D.L Richardson;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
194
TITLE: Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study
AUTHORS: Raymond J Osborne; Virginia Filiaci; Julian C Schink; Robert S Mannel; Angeles Alvarez Secord; Joseph L Kelley; Diane Provencher; David Scott Miller ; Allan L Covens; Janice M Lage;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 7
INDEXED IN: Scopus CrossRef: 126
IN MY: ORCID | CIÊNCIAVITAE
195
TITLE: Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors  Full Text
AUTHORS: D.B Manders; S.C Purinton; J.S Lea; D.L Richardson; David Scott Miller ; S.M Kehoe;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef: 1
IN MY: ORCID | CIÊNCIAVITAE
196
TITLE: PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment  Full Text
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Clinical Ovarian Cancer, VOLUME: 4, ISSUE: 2
INDEXED IN: Scopus CrossRef
IN MY: ORCID | CIÊNCIAVITAE
197
TITLE: Survival impact of clinical trials in patients with recurrent cervical cancer  Full Text
AUTHORS: Nagel, C; Denson, W; Rogers, P; Manders, D; Richardson, D; Kehoe, S; David Scott Miller ; Lea, J;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
198
TITLE: The role of lymphadenectomy in endometrial cancer
AUTHORS: Siobhan M Kehoe; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Clinical Obstetrics and Gynecology, VOLUME: 54, ISSUE: 2
INDEXED IN: Scopus CrossRef: 25
IN MY: ORCID | CIÊNCIAVITAE
199
TITLE: Third-line salvage chemotherapy for recurrent cervical cancer.
AUTHORS: Manders, DB; Purinton, SC; Lea, J; David Scott Miller ; Kehoe, SM; Richardson, DL;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 15_suppl
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
200
TITLE: A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial. A Gynecologic Oncology Group Trial
AUTHORS: Russell J Schilder; John A Blessing; Mark S Shahin; David Scott Miller ; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch;
PUBLISHED: 2010, SOURCE: International Journal of Gynecological Cancer, VOLUME: 20, ISSUE: 7
INDEXED IN: Scopus CrossRef: 13
IN MY: ORCID | CIÊNCIAVITAE
Page 20 of 32. Total results: 317.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service